Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0154)
Name |
Sodium Selenite
|
||||
---|---|---|---|---|---|
Synonyms |
SODIUM SELENITE; Disodium selenite; 10102-18-8; Natriumselenit; Selenious Acid Disodium Salt; Selenious acid, disodium salt; Disodium selenium trioxide; Selenite sodium; disodium;selenite; Sodium selenite anhydrous; CCRIS 1260; HSDB 768; UNII-HIW548RQ3W; EINECS 233-267-9; HIW548RQ3W; Selenious acid, sodium salt (1:2); MFCD00003489; Selenious acid (H2SeO3), disodium salt; DTXSID0032077; CHEBI:48843; NSC-347466; DTXCID8012077; EC 233-267-9; NSC 347466; 10102-18-8(disodiumsalt)7782-82-3(monosodiumsalt); Sodium selenite (JAN); SODIUM SELENITE [JAN]; dinatriumselenit; Natriumselenit [German]; SODIUM SELENITE (EP MONOGRAPH); SODIUM SELENITE [EP MONOGRAPH]; Selenite, Sodium; Selenite, Disodium; NA2630; Selenous Acid Disodium Salt; Aselend; Selenous Acid, Disodium Salt; Sodium-selenite; H2-O3-Se.1/2Na; Aselend (TN); Sodium Selenite,(S); SODIUM SELENITE [MI]; SODIUM SELENITE [HSDB]; CHEMBL112302; SODIUM SELENITE [VANDF]; DISODIUM SELENITE [INCI]; SODIUM SELENITE [WHO-DD]; BVTBRVFYZUCAKH-UHFFFAOYSA-L; SODIUM SELENATE (NA2SEO3); Tox21_202977; SODIUM SELENITE [GREEN BOOK]; AKOS015912461; SODIUM SELENIUM OXIDE(NA2SEO3); Sodium selenite [NA2630] [Poison]; NCGC00260523-01; CAS-10102-18-8; SELENIOUS ACID(H2SEO3), DISODIUM SALT; D10530; SODIUM SELENITE HIGH PURITY GRADE 100G; Q414626
Click to Show/Hide
|
||||
Structure |
![]() |
||||
3D MOL
|
|||||
Formula |
Na2O3Se
|
||||
IUPAC Name |
disodium;selenite
|
||||
Canonical SMILES |
[O-][Se](=O)[O-].[Na+].[Na+]
|
||||
InChI |
InChI=1S/2Na.H2O3Se/c;;1-4(2)3/h;;(H2,1,2,3)/q2*+1;/p-2
|
||||
InChIKey |
BVTBRVFYZUCAKH-UHFFFAOYSA-L
|
||||
PubChem CID |
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Glioblastoma | ICD-11: 2A00 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model | U-87MG cells | Glioblastoma | Homo sapiens | CVCL_GP63 |
HeLa cells | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
MCF-7 cells | Breast carcinoma | Homo sapiens | CVCL_0031 | |
PC-3 cells | Prostate carcinoma | Homo sapiens | CVCL_0035 | |
HT-29 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0320 | |
SVG p12 cells | Normal | Homo sapiens | CVCL_3797 | |
A-172 cells | Glioblastoma | Homo sapiens | CVCL_0131 | |
HT-1080 cells | Fibrosarcoma | Homo sapiens | CVCL_0317 | |
HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 | |
Response regulation | Sodium selenite (SS) down-regulates ferroptosis regulators; solute carrier family 7 member 11 (SLC7A11), glutathione (GSH), and glutathione peroxidase 4 (GPx4), while it up-regulates iron accumulation and lipid peroxidation (LPO) in Glioblastoma. | |||